Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders

Picture a new bioprocess automation project: ambitious, expensive, and packed with promise. But after months of development, your team discovers a flaw that could have been caught with a simple mockup and a few sticky notes on a whiteboard. This episode confronts the real cost of skipping discovery, premature automation, and the myth that faster engineering always means faster solutions.

Anthony Catacchio, CEO of Product Insight, continues his conversation with David Brühlmann to untangle the realities of automation strategy in biotech. Drawing from years of building robotics for high-stakes labs, Anthony explores why "minimum testable product" consistently outperforms "minimum viable product" when budgets, timelines, and patient outcomes are on the line.

Highlights from the episode:

• When custom robotics development is genuinely justified — and the conditions that determine whether a large-scale automation investment makes sense for your organization (02:59).
• Tech demos and usability demos: how to test the hardest parts of your system concept in isolation before committing to full development (06:37).
• Minimum testable product vs. minimum viable product: why rushing to viable in hardware development is a costly mistake, and how controlled pilot deployments generate the learning that actually accelerates your program (07:37).
• Why testing in the real operating environment — not a simulated lab setting — is the only way to surface the hidden requirements that will determine whether your automation succeeds or fails (08:29).
• The "go fever" trap: why problems discovered late in development get buried rather than fixed, and how front-loading validation protects both your timeline and your budget (10:16).
• The single most practical question a biotech scientist can ask to determine whether a process is a genuine automation candidate: how much are you thinking while you do it? (16:02).
• Where AI and machine learning deliver real value in bioprocess research — and why the more urgent question is not how to automate a process, but how to redesign it to produce better data (17:59).
• Why capital equipment in biotech labs will need to change fundamentally to collect the volume and quality of data required to make AI-driven insights meaningful (19:01).

Smart insight: Automation is not a technology problem, it is a systems development and requirements development problem. The teams that deeply understand their process and environment before touching a line of code or a line of engineering will always outperform those that do not. As Anthony puts it: you need to look at the whole picture.

Connect with Anthony Catacchio:

LinkedIn: www.linkedin.com/in/anthony-catacchio-b881581b

Product Insight website: www.productinsight.com

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

Many bioprocess automation projects fail, not because the technology is wrong, but because no one clearly defined the problem before buying the robot.

In this episode, David Brühlmann sits down with Anthony Catacchio, CEO of Product Insight, to explore why rigorous system design and honest problem definition matter more than any individual technology, and how industrial robotics expertise translates directly into smarter lab automation.

Highlights from the episode:

• Why biotech's "special case" mindset around automation is costing companies time and money — and what industrial robotics already has figured out (02:45).
• How Anthony's cross-industry career — from surgical devices to warehouse robotics — shaped a process-first approach to system design (05:05).
• The automation paradox: how to increase throughput and reduce errors without eliminating the expert human judgment your process depends on (09:13).
• Vision-guided robotics, AGVs, and quadrupeds: what has genuinely changed in capability and what that means for bioprocess applications (11:21).
• Human-bot testing: the low-cost validation method that reveals workflow flaws before a single robot is purchased (15:07).
• The $1M vs. $10K decision: a real case study where the right answer was walking away from automation entirely (15:54).
• Why talking a client out of an expensive project is sometimes the highest-value service a technical consultant can deliver (17:38).
• Building long-term credibility by recommending the simplest solution that actually solves the problem (19:24).

Smart insight: The most expensive automation mistake happens at the whiteboard, not on the manufacturing floor. Define the problem with surgical precision before you ever evaluate a solution.

In Part 2, the conversation continues with a deeper look at building automation systems that deliver practical solutions to bioprocessing challenges without overengineering.

Tune in for practical strategies and honest reflections on automation, system design, and the importance of clear problem definition in biotech hardware development.

Connect with Anthony Catacchio:

LinkedIn: www.linkedin.com/in/anthony-catacchio-b881581b

Product Insight website: www.productinsight.com

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

How solid is your CMC foundation—and what happens if it cracks under pressure?

David Brühlmann welcomes Henri Kornmann, former Head of Biologics Innovation Centre at Ferring Pharmaceuticals. From junior CMC scientist at Merck to leading Ferring Pharmaceuticals' first gene therapy approval for bladder cancer, Henri has moved repeatedly between CMC development, GMP manufacturing, and due diligence across some of the industry's most complex programs.

His “house building” approach demystifies CMC’s complexity, showing why early diligence paired with regulatory fluency and scientific insight pays dividends for years.

Tune in to hear Henri’s practical wisdom distilled through real-world analogies:

• Building a strong CMC foundation in early phases and why later fixes can be costly or impossible (02:45)
• Scaling up: supplying Phase 3 with the final commercial process, including robustness and supply chain strategies such as dual sourcing critical raw materials (03:23)
• Process validation explained: FDA’s three stages, from control strategy justification to continued verification (05:15)
• Process Performance Qualification (PPQ): what it is, how many batches are needed, and optimizing timing (07:43)
• Handling lifecycle changes: maintaining process control, adapting to deviations, and improving systems after regulatory approval (09:34)
• Managing teams, stakeholders, and cross-functional collaboration in CMC programs (11:49)
• Importance of good project management, access to scientific expertise, and interpreting guidelines for your specific program (12:27)
• The “half scientist, half lawyer” analogy for mastering both technical and regulatory aspects (15:08)

Smart insight:

Never underestimate CMC. If you do, you will pay for it later.

If this topic resonates with you, here are a few related episodes where we dive deeper into building strong CMC foundations and avoiding costly development mistakes:

• Episodes 199 - 200: Mastering Quality by Design: From Product Failures to Commercial Success in Biologics CMC Development
• Episodes 189 - 190: Why Smart Biotech Founders Plan CMC First (While Competitors Burn Cash Later)
• Episodes 23 - 24: Strategies for Success: Master CMC Development with Gene Lee
• Episodes 57 - 58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls with Matthias Müllner

Connect with Henri Kornmann:

LinkedIn: www.linkedin.com/in/henri-kornmann-9b6869

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

Seventy percent of FDA Complete Response Letters have a CMC root cause. Most of those failures trace back to decisions made years earlier. Decisions that felt minor at the time and proved impossible to fix later.

Henri Kornmann has spent two decades making those decisions the right way. From junior CMC scientist at Merck to leading Ferring Pharmaceuticals' first gene therapy approval for bladder cancer, Henri has crossed between CMC development, GMP manufacturing, and due diligence across some of the industry's most complex programs. His conclusion: a CMC program is like building a house. Get the foundation wrong and no amount of late-stage effort will save you.

In Part 1, Henri reveals the decisions that cannot be undone and how to get them right from the start.

What you will learn:

• Evolution of cell bank technology and regulatory expectations (00:33)
• The impact of weak CMC foundations on late-stage failure (00:51)
• Lessons learned from Ferring’s gene therapy approval and CMC gap analysis (06:51)
• FDA statistics on CMC issues in INDs and response letters (08:07)
• Critical early decisions: cell bank clonality and proper storage practices (10:22)
• The importance of comprehensive raw material documentation (12:29)
• Early analytical characterization and discovering molecular “funkiness” before phase trials (13:41)
• Supply strategy for phase 2—why stability and batch knowledge matter (14:49)
• Introduction to critical quality attributes (CQA), process parameters, and quality-by-design principles (15:52)
• Common pitfalls in CQA identification and continued process verification (17:01)

Smart insight:

The therapies that reach patients aren't built on heroic late-stage rescues. They're built on disciplined early decisions: the right cell bank, the right analytics, the right documentation. Henri's message is unambiguous: there are CMC mistakes you can fix later, and there are CMC mistakes you cannot. Knowing the difference is the foundation of every successful biologics program.

In Part 2, Henri walks through scale-up to commercial manufacturing, process validation stages 1 through 3, post-approval control strategy, and the project management and regulatory fluency that separate successful CMC leaders from the rest.

If this topic resonates with you, here are a few related episodes where we dive deeper into building strong CMC foundations and avoiding costly development mistakes:

• Episodes 199 - 200: Mastering Quality by Design: From Product Failures to Commercial Success in Biologics CMC Development
• Episodes 189 - 190: Why Smart Biotech Founders Plan CMC First (While Competitors Burn Cash Later)
• Episodes 23 - 24: Strategies for Success: Master CMC Development with Gene Lee
• Episodes 57 - 58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls with Matthias Müllner

Connect with Henri Kornmann:

LinkedIn: www.linkedin.com/in/henri-kornmann-9b6869

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

What if the future of sustainable manufacturing required no sugar feedstocks, generated minimal waste, and operated carbon-neutral from day one? Ocean-derived cyanobacteria are making this possible—but the path from promising strain to profitable business is littered with synthetic biology casualties. This episode reveals the strategic decisions that separate winners from failures.

In Part 2, Tim Corcoran, CEO and Co-Founder of Deep Blue Biotech, exposes the hard truths about commercializing photosynthetic manufacturing: why most synthetic biology companies died when capital dried up in 2023, which infrastructure gaps nearly derail cyanobacteria scale-up, and why building one facility beats building ten. With three decades navigating commercial biotech and operations, Tim shares the disciplined commercialization framework that transforms scientific breakthroughs into economically viable platforms.

Topics covered:

• The strategic advantage of B2B commercialization in consumer care biotech (02:46)
• Overcoming infrastructure limitations for photobioreactor scale-up and partnering with specialized CMOs (04:50)
• Building a pilot facility and moving toward technology licensing for global reach (05:33)
• Location choices for production facilities—comparing natural light, skilled labor, and electricity costs in Portugal and Iceland (08:57)
• Impact of electricity usage for LED-supported photosynthesis on business viability (10:45)
• What distinguishes successful laboratory-to-market biotech companies from those that fail, especially in challenging financial environments (11:53)
• Practical advice for scientists considering entrepreneurship, including partnering with business-minded collaborators and exploring university innovation programs (14:08)
• Speculation on the broader applications and future of synthetic biology, from biofuels to biodegradable materials and CO₂-absorbing products (15:27)
• The importance of aligning technical innovation with commercial expertise to create enduring impact (16:38)

Strategic insight:

Breakthrough science needs disciplined commercialization. Align what your technology naturally excels at with market needs, start where value is highest, and leverage partnerships to scale. As Deep Blue Biotech shows, this is how innovations move from the lab to making a real-world impact.

Explore the full story and hear Tim’s advice for both founders and innovators.

If you’re interested in other unconventional biological platforms reshaping biomanufacturing, don’t miss:

• Episode 163-164: How Moss Enables Production of Unproducible Protein Therapeutics with Andreas Schaaf
• Episodes 141-142: How Microalgae Cuts Antibody Costs by 70% and Redefines Biomanufacturing with Muriel Bardor

Connect with Tim Corcoran:

LinkedIn: www.linkedin.com/in/tim-corcoran-5b10121/

Deep Blue Biotech: www.deepbluebiotech.com

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

The chemicals industry remains locked into carbon-intensive, fossil-based manufacturing. Even engineered microbes like yeast or E. coli depend on expensive sugar feedstocks while generating significant waste. What if a photosynthetic organism could eliminate those constraints entirely—while commanding premium pricing as "ocean-derived"?

On the Smart Biotech Scientist Podcast, Tim Corcoran, CEO and Co-Founder of Deep Blue Biotech, reveals how a recently discovered fast-growing marine cyanobacteria strain is unlocking carbon-neutral chemical production at costs below conventional fermentation. With his background spanning economics, operations, and innovation commercialization, Tim challenges conventional assumptions about synthetic biology scale-up, market entry strategy, and what actually separates successful biotechs from valley-of-death casualties.

Key topics discussed:

• Tim Corcoran’s background in commercial roles, his pivot to biotech, and the founding story of Deep Blue Biotech (03:41)
• Overview of cyanobacteria biology: photosynthetic efficiency and its legacy in Earth's atmosphere (07:22)
• What makes the discovered ocean-based strain unique—and its advantages in robustness, growth rate, and use in personal care (08:27)
• Commercial challenges and scientific limitations that have made cyanobacteria difficult to industrialize—plus recent breakthroughs (9:38)
• Comparison with legacy hosts such as E. coli, yeast, microalgae: efficiency, feedstocks, genetic tractability, and downstream processing
• (11:02)
• The significance of direct secretion for lowering production costs and reducing CO₂ footprint (14:38)
• Scale-up strategies with photobioreactors: modularity, light and CO₂ management, and future tech improvements (15:17)
• Commercial strategy: starting with high-value personal care hyaluronic acid, regulatory considerations, and the rationale for this approach (17:17)
• The importance of aligning scientific innovation with market needs and early customer discovery (20:31)
• Long-term vision: potential for cyanobacteria in sustainable production of commodity chemicals like biofuels and the impact on global emissions (22:04)

Strategic insight:

Deep Blue Biotech's "premium-first commercialization" mirrors Tesla's playbook: start with high-margin applications ($2,000/kg hyaluronic acid for personal care) to generate immediate revenue and prove the platform. These early profits fund continuous strain engineering and process optimization, progressively driving down cost-of-goods while improving volumetric productivity. Only after establishing economic viability at premium pricing does the company target large-volume commodity markets—sustainable fuels, industrial chemicals—where success requires demonstration of competitive economics at industrial scale.

Discover how this photosynthetic organisms could decarbonize entire chemical supply chains while improving manufacturing economics. Part 2 reveals the strategic decisions separating synthetic biology winners from failures, photobioreactor infrastructure challenges, and why licensing beats building multiple facilities.

If you’re interested in other unconventional biological platforms reshaping biomanufacturing, don’t miss:

• Episode 163-164: How Moss Enables Production of Unproducible Protein Therapeutics with Andreas Schaaf
• Episodes 141-142: How Microalgae Cuts Antibody Costs by 70% and Redefines Biomanufacturing with Muriel Bardor

Connect with Tim Corcoran:

LinkedIn: www.linkedin.com/in/tim-corcoran-5b10121/

Deep Blue Biotech: www.deepbluebiotech.com

Next step:

Need fast CMC guidance? → Get rapid CMC decision support 

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

How early in process development should you address glycosylation? This episode presents the case for co-optimizing glycan profiles with productivity from initial process characterization. Deferring glycosylation characterization until after titer targets are met introduces risk: quality attribute gaps discovered late in development force process re-optimization, extended timelines, and potential cell line reselection. Media supplementation enables earlier intervention—tuning glycan distribution as a process parameter from the beginning of cell line and media development rather than as a remediation strategy.

David Brühlmann outlines the experimental protocol for validating raffinose supplementation, including decision criteria for proceeding or terminating at each development stage. The discussion addresses process design space requirements, analytical monitoring strategy, and the experimental variables that determine when media-based glycan tuning is appropriate versus when alternative approaches are needed.

Highlights from the episode:

• When to use (and not use) raffinose in your development program, including limitations and effectiveness windows (00:30)
• Essential protocol: three experiments over eight weeks to validate raffinose for your process, with clear go/no-go criteria (04:09)
• Why individualized mannose tracking (Man5, Man6, Man7, Man8) is crucial for meaningful results (01:06)
• Managing osmolality: why it matters and how to control it in your experiment (04:36)
• Advice on scaling up: moving from small-scale screens to benchtop bioreactors and stress-testing your process (07:48)
• Three key mistakes to avoid when implementing raffinose, including lessons from analytical oversight, incomplete design mapping, and feed interference (09:08)
• Integrating glycosylation as a core part of process design, not just a secondary consideration after titer optimization (13:10)

Strategic insight:

Sequential optimization of productivity followed by glycosylation introduces development risk: quality attribute deviations discovered after process lockdown require costly re-optimization cycles. Parallel development of titer and glycan specifications from initial cell line characterization reduces this risk by establishing feasible operating windows early in the development timeline.

Are you planning your next recombinant protein scale-up? Hear how David’s rule-of-three protocol and battle-tested lessons can help you optimize faster and avoid painful late-stage surprises.

Resources: Journal of Biotechnology, 2017, volume 252, pages 32 to 42

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

When your biosimilar analytical data shows 1.4% high mannose against a 6% reference product specification, you face limited options: process temperature shifts that compromise titer, kifunensine supplementation that requires extensive regulatory justification, or 12-18 months to reclone and revalidate. Media supplementation offers an alternative pathway—tuning glycan profiles through formulation adjustments rather than cell line or process re-engineering.

In this episode, David Brühlmann presents the experimental development of a media supplementation strategy that achieved 2.8-fold increases in high mannose glycans across multiple CHO cell lines. Drawing from research published in the Journal of Biotechnology (2017, 252:32-42), the discussion covers the mechanism of raffinose-mediated glycan processing arrest, the experimental variables that initially obscured the effect, and the process development considerations for implementing media-based glycan tuning.

The episode examines N-glycan biosynthesis in CHO cells, regulatory comparability requirements for biosimilar glycosylation profiles, and the experimental framework for evaluating media supplementation as a glycan control strategy.

Highlights from the episode:

• The unexpected link between dietary raffinose and reduced athletic performance, and its connection to bioprocessing (01:11)
• A clear primer on the importance of glycosylation for biosimilar drugs and regulatory approval (02:43)
• Common challenges when glycan profiles don't match reference products, and why high mannose glycans matter (04:19)
• A review of industry strategies (temperature shifts, enzyme inhibitors, cell line reengineering) and their pitfalls (05:33)
• Mechanistic insights into how raffinose alters glycan processing in CHO cells (07:05)
• Key experimental findings on raffinose concentration, osmolality control, and practical lab troubleshooting (09:48)
• Application stories and regulatory considerations for implementing raffinose-based media adjustments (13:47)
• Closing thoughts on process optimization, regulatory impact, and what to expect in Part 2 (15:11)

Strategic insight:

Implementing raffinose as a media supplement is straightforward, regulatory-friendly, and cost-effective. It does not involve genetic engineering or enzyme inhibitors and is easily sourced as a GMP-grade material. For programs approaching submission with glycan comparability gaps, media-based tuning offers a process optimization pathway that maintains existing cell lines and manufacturing platforms while addressing critical quality attribute specifications.

Listen to this episode of the Smart Biotech Scientist Podcast to learn David’s best strategies for rapid, regulatory-friendly glycosylation control.

If you want to transform your glycoengineering workflow, keep an eye (and ear) out for the next episode of the Smart Biotech Scientist Podcast. Your path to regulatory success might be as simple as a pinch of raffinose.

Resources: Journal of Biotechnology, 2017, volume 252, pages 32 to 42

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

Hard-to-treat cancers like pancreatic ductal adenocarcinoma (PDAC) have long defied conventional therapies. Radiopharmaceuticals, combining targeted therapy with diagnostic power, are creating new opportunities in precision oncology.

Host David Brühlmann speaks with Bryan Miller of Crown Bioscience, who explains how Crown's strategic partnerships, rigorous quality standards, and adaptive study design are shaping radiopharmaceutical development—delivering speed, safety, and real clinical impact.

In this episode, you'll learn:

• The promise and practical implications of theranostics—agents used for both diagnosis and treatment (02:44)
• Definitions and distinctions between CDX (cell line-derived xenograft) and PDX (patient-derived xenograft) models, and why PDX models better recapitulate tumor heterogeneity (05:11)
• Strategies for building more predictive, clinically relevant research models (06:09)
• Balancing rapid innovation with rigorous quality standards—why robust QC systems enable speed without compromising safety (08:01)
• Key advice for scientists entering radiopharmaceutical development, including how to choose the right research partners (09:53)
• Why effective collaboration between biotech companies and CROs is akin to a well-chosen partnership (10:50)
• The future outlook for radiopharmaceuticals and their impact on hard-to-treat cancers (12:21)

Strategic insight:

Focusing on theranostic radiopharmaceuticals—agents that combine diagnostics and therapy—offers a high-impact strategy for hard-to-treat cancers like PDAC. By enabling simultaneous patient stratification and targeted treatment, theranostics can accelerate development, improve clinical outcomes, and create a competitive advantage in areas where traditional therapies are limited.

Where do you see radiopharmaceuticals and advanced preclinical models making the biggest impact in oncology or beyond?

Explore the full conversation to learn how Bryan Miller and Crown Bioscience are scaling innovation for the next generation of cancer therapies.

Connect with Bryan Miller:

LinkedIn: www.linkedin.com/in/bryan-miller-148344aa

Crown Bioscience: www.crownbio.com

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

Imagine treating cancer with the precision of a guided missile—delivering radioactive payloads directly to tumor cells. Radiopharmaceuticals are reshaping cancer diagnostics and therapy by pairing tumor-targeting molecules with radioisotopes for diagnosis or therapy. But what does it really take to develop these therapies, and why is interest from scientists, biotech companies, and pharma accelerating?

In this episode, we're joined by Bryan Miller, Director of Scientific and Technical Operations at Crown Bioscience UK. From a PhD in cardiac disease to leading preclinical oncology and radiopharmaceutical programs, Bryan brings hands-on insight into building advanced cancer models and translating innovative therapies from bench to clinic.

Topics discussed include:

• Bryan Miller's path from cardiac disease research to leading preclinical cancer model development (03:03)
• Crown Bioscience's comprehensive cancer model platforms, from organoids to PDX and humanized in vivo models (04:05)
• How radiopharmaceuticals differ from traditional chemotherapies in terms of safety and speed, including the concept of theranostics (07:32)
• The reasons behind the surge of interest in radiopharmaceuticals within science and industry (09:04)
• The importance of selecting the right preclinical model for success—and how AI and data-driven approaches will shape future workflows (10:11)
• Critical pitfalls and unique technical challenges in radiopharmaceutical drug development (12:46)
• Crown Bioscience's collaborative approach with Medicines Discovery Catapult to navigate the complexities of radiopharmaceutical research (13:35)
• The diverse client needs, from small startups to global pharma companies, and how mature their development programs can be (14:20)
• Strategies for scaling preclinical and translational capabilities to meet growing demand in radiopharmaceutical studies (16:04)

Strategic insight:

Radiopharmaceutical success requires integrated design from the start—combining precise model selection, targeting strategy, isotope choice, linker chemistry, and rigorous QC. Programs that establish this comprehensive foundation early move faster and with higher translational confidence than those addressing these elements sequentially or treating any aspect as a downstream refinement.

If you're curious about the real challenges of drug development, the rise of theranostics, and how data-driven approaches (including AI) are shaping preclinical workflows, this episode delivers actionable strategies and insider perspectives for scientists and biotech innovators alike.

Connect with Bryan Miller:

LinkedIn: www.linkedin.com/in/bryan-miller-148344aa

Crown Bioscience: www.crownbio.com

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show